Goldman Sachs maintains Neutral on Mitsui Chemicals: new CEO pushes portfolio transformation, but near-term earnings momentum remains weak

Overview

Goldman Sachs updated its view around Mitsui Chemicals' new CEO business briefing. Management emphasized leveraging globally competitive products and technologies, industry restructuring momentum, and investment in growth areas to build the company into a "truly global specialty company." The report acknowledges this transformation direction, especially global expansion, M&A, and growth-business positioning, but believes weak demand, intense competition, rising raw material and fuel costs, and low operating rates in some businesses will weigh on overall profit growth in the short term, and therefore maintains a Neutral rating.

Core views

The core judgment is that the strategic direction is positive, but earnings validation will still take time. B&GM will continue to advance its spin-off and ethylene cracker integration; Life & Healthcare is supported by vision care, agrochemicals, and emerging-market expansion; Mobility depends on PP compound, growth in India and Brazil, and the ramp-up of the new Tafmer@ plant in Singapore; ICT is driven by ICROS Tape growth, but EUV pellicle demand remains weak. Goldman Sachs also notes that the handling and restructuring of underperforming businesses such as ARRK and nonwoven fabrics will affect the credibility of the portfolio transformation.

Analysis framework

The report uses management's business briefing as the core input and updates earnings forecasts, valuation target price, and relative sector rating in conjunction with segment business progress, regional expansion, M&A success rates, and cost and demand pressures. The analytical focus is not a single event catalyst, but whether the new CEO can turn the 100-day plan, B&GM restructuring, and investment in growth areas into sustainable profit improvement.

Methodology notes

• Valuation methodologyEV/GCI and CROCI/WACC correlation

  Derive the target price using the relationship between the materials sector's FY3/27-28E average EV/GCI and CROCI/WACC.

  Goldman Sachs uses a 5% WACC and a 0.7x cash return multiple, representing a 30% discount to the sector average, to arrive at a 12-month target price of ¥2,310.

• Factor frameworkGS Factor Profile

  Compare stocks across four attributes: Growth, Financial Returns, Multiple, and Integrated.

  This framework uses forward sales, EBITDA, EPS, ROE, ROCE, CROCI, and valuation multiples to form percentiles, helping assess relative growth, return, and valuation characteristics.

• Event and M&A frameworkM&A Rank

  Uses a score of 1 to 3 to measure the likelihood of a company becoming an acquisition target.

  Mitsui Chemicals has an M&A Rank of 3, indicating a low probability of acquisition, and therefore M&A is typically not factored into the target price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Mitsui Chemicals Inc. (4183.T)

  Research target and Japanese chemicals sector stock.

  Strengths

  The new CEO has proposed a clear transformation direction, with globally competitive products and technologies, and overseas sales in growth areas already approaching 70%.

  Weaknesses

  Near-term company-wide profit growth momentum is insufficient, facing weak demand, intense competition, and raw material and fuel cost pressure.

  Comparison

  Maintains Neutral relative to the covered sector, with only 4.8% implied upside to the target price.

  Risks

  Raw material costs, market conditions, exchange rates, competition, and demand changes could all affect the target price.

• Basic & Green Materials (B&GM)

  Core business for portfolio transformation, petrochemical restructuring, and capital efficiency improvement.

  Strengths

  The company has secured naphtha supply for the next two months and plans to stabilize cash flow through price increases and postponement of non-urgent spending.

  Weaknesses

  Low operating rates and rising raw material and fuel costs weigh on earnings forecasts.

  Comparison

  The spin-off target remains FY3/28, with the path including polyolefin integration in FY3/27, a single ethylene cracker in Chiba in FY3/28, and a single ethylene cracker in western Japan around FY3/31.

  Risks

  Middle East conditions, naphtha supply, price pass-through, and delays in restructuring execution.

• Life & Healthcare Solutions

  One of the growth areas, including profit-driving businesses such as vision care and agrochemicals.

  Strengths

  Vision care is supported by replacement glass and low-refractive-index lenses, emerging-market expansion, and M&A in adjacent coating businesses; agrochemicals have a long-term operating profit CAGR of +12%.

  Weaknesses

  FY3/26 was affected by a gas leak at the Omuta plant, while inventory adjustments for dinotefuran in Brazil created short-term pressure.

  Comparison

  Compared with traditional chemical businesses, this segment has higher medium-term growth certainty, but the pace of recovery still needs to be monitored.

  Risks

  Vision care capacity recovery, Brazil inventory adjustments, and slower-than-expected sales growth for products such as Tenebenal.

• Mobility Solutions

  One of the growth areas, centered on automotive materials, PP compound, and Tafmer@.

  Strengths

  ASEAN ROS exceeds 15%, and the Americas are around 15%; PP compound is globally No. 2, with growth potential in India and Brazil.

  Weaknesses

  FY3/26 volume was weaker than original guidance, and there is uncertainty over the ramp-up speed of the large new Tafmer@ plant in Singapore.

  Comparison

  The company plans to expand from Japanese OEMs to local manufacturers and differentiate through high-performance composite materials.

  Risks

  Declining demand for automotive materials, higher depreciation, and weaker-than-expected volume growth.

• ICT Solutions

  One of the growth areas, mainly including semiconductor manufacturing materials.

  Strengths

  ICROS Tape enhanced evaluation and development functions at the Taiwan plant, with FY3/26 volume growing about 20% and dicing applications such as HBM expanding.

  Weaknesses

  EUV pellicle demand has been weak over the past few quarters, attracting market attention but lacking sufficient validation.

  Comparison

  DUV pellicle demand remains solid, while EUV pellicle needs to establish leadership through lifetime, transmittance, and quality control.

  Risks

  Competition from new CNT pellicle entrants, slower-than-expected yield improvements, and semiconductor capex volatility.

Key data

• RatingNeutralMaintains a neutral stance relative to Goldman Sachs' covered Japanese chemicals sector.
• 12-month target price¥2,310Raised from ¥2,240, mainly due to the valuation year roll-forward.
• Current price and implied upside¥2,204；4.8%Limited upside is an important reason for maintaining Neutral.
• FY3/27E core operating profit forecast revision-13%Reflects low operating rates in B&GM, rising raw material and fuel costs, and declining demand for automotive materials.
• FY3/28E core operating profit forecast revision-8%Also reflects pressure from costs, demand, and capacity utilization.
• Market capitalization¥811.3bn / $5.1bnDisclosed on the report's key data page.
• Enterprise value¥1.6tr / $10.3bnDisclosed on the report's key data page, including lease-related net debt and EV basis.
• 3-month average daily trading value¥6.8bn / $43.0mnUsed to measure stock liquidity.
• Overseas sales share in growth areasabout 70%The Americas, India, and Asia are identified as key regions.
• ICROS Tape volume growthabout +20% yoyDriven in FY3/26 by demand for semiconductor manufacturing tape and improvements in capacity and development capabilities.
• Agrochemical operating profit CAGR+12% CAGRSupported in FY3/12-26 by four products including dinotefuran and Tenebenal.
• M&A Rank3Represents a low acquisition probability and has limited impact on the target price.
• Conflict of interest disclosureGoldman Sachs disclosed shareholding and client relationshipsThe report discloses that Goldman Sachs held 5% or more of the common shares of Mitsui Chemicals Inc. at the end of the month prior to the report and has or intends to seek investment banking business relationships.

Impact & implications

The report's investment implication is cautious: management's roadmap improves the medium- to long-term transformation narrative, but near-term earnings forecasts were lowered, and the target price increase is insufficient to create a clear buying opportunity. Investors should treat the subsequent 100-day plan, execution of B&GM restructuring, orders in growth businesses, and disposal of underperforming businesses as key validation points for whether the rating can be upgraded.

Risks

• Rising or falling raw material and fuel costs will directly affect earnings and the target price.
• Improvement or deterioration in market conditions will change demand and pricing pass-through ability.
• Depreciation or appreciation of the yen will affect translation of overseas operations and the cost-profit structure.
• Easing or intensifying competition will affect margins and share in growth areas.
• If demand for automotive materials, Tafmer@, and EUV pellicles is below expectations, it could drag on growth-business performance.
• If B&GM restructuring, spin-off, and cracker integration are delayed, it could weaken the narrative of improved capital efficiency.
• If disposal or improvement of underperforming businesses such as ARRK and nonwoven fabrics does not go smoothly, it could affect the credibility of the portfolio transformation.

What to watch

• Details of the 100-day group plan led by the CFO, CTO, CHRO, and head of production technology.
• The FY3/28 B&GM spin-off target, as well as progress on polyolefin integration in FY3/27, Chiba cracker integration in FY3/28, and western Japan integration around FY3/31.
• The impact of Middle East conditions on naphtha procurement, operating rates, price increases, and cash flow management.
• The speed of recovery in the vision care business from the impact of the Omuta plant accident.
• The digestion of Brazil dinotefuran inventory adjustments, and whether products such as Tenebenal can make up the growth.
• Ramp-up of the new Tafmer@ plant in Singapore, volume growth, and depreciation pressure.
• Continued growth of ICROS Tape in dicing applications such as HBM, as well as recovery in EUV pellicle demand and CNT competition.
• Whether ARRK will be sold, whether Kulzer's reform is nearing its target, and the direction for handling underperforming businesses such as nonwoven fabrics in FY3/27.